Results 141 to 150 of about 6,738 (290)

Preventing gambling-related harm among adolescents (PRoGRAM-A): an embedded multi-modal process evaluation in a pilot cluster random control trial

open access: yesBMC Public Health
Background and Aims Young people’s engagement in gambling can be linked to gambling-related harm. This can cause stress, anxiety, relationship issues, debt, and lost opportunities.
Martine Miller   +11 more
doaj   +1 more source

Charting a path towards a public health approach for gambling harm prevention. [PDF]

open access: yesJ Public Health (Berl), 2021
Price A, Hilbrecht M, Billi R.
europepmc   +1 more source

Increased Elbow Valgus Torque During Pitching Is Not a Risk Factor for Medial Elbow Injuries in Young Baseball Pitchers: A Prospective Cohort Study

open access: yesArthroscopy, EarlyView.
Purpose To examine the relationship between elbow valgus torque during pitching and the occurrence of medial elbow injuries in young baseball pitchers prospectively. Methods Between 2019 and 2023, 361 male pitchers aged 9 to 12 years were enrolled. Pitchers with a history of elbow injury or who had not served as pitchers in baseball games for ≥1 year ...
Akira Saito   +6 more
wiley   +1 more source

What is the evidence that advertising policies could have an impact on gambling-related harms? A systematic umbrella review of the literature

open access: hybrid, 2023
Ellen McGrane   +7 more
openalex   +1 more source

Assessing potential brief screening questions for use within different social care‐related contexts to identify individuals experiencing gambling‐related harms: A scoping review [PDF]

open access: hybrid, 2022
Cat Forward   +10 more
openalex   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results from the Phase 2 TULIP‐LN Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon (IFN) signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, NCT02547922). We studied
Andrea Fava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy